NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Department of Respiratory Medicine , Maastricht, The Netherlands.
Expert Rev Respir Med. 2021 Jan;15(1):103-115. doi: 10.1080/17476348.2021.1843429. Epub 2020 Nov 10.
: Muscle impairments are prevalent in COPD and have adverse clinical implications in terms of physical performance capacity, disease burden, quality of life and even mortality. During acute exacerbations of COPD (AECOPDs) the respiratory symptoms worsen and this might also apply to the muscle impairments. : This report includes a review of both clinical and pre-clinical peer-reviewed literature of the past 20 years found in PubMed providing a comprehensive view on the role of AECOPD in muscle dysfunction in COPD, the putative underlying mechanisms and the treatment perspectives. : The contribution of AECOPD and its recurrent nature to muscle impairment in COPD cannot be ignored and can be attributed to the acutely intensifying and converging disease-related drivers of muscle deterioration, in particular disuse, systemic inflammation and corticosteroid treatment. The search for novel treatment options should focus on the AECOPD-enhanced drivers of muscle dysfunction as well as on the underlying, mainly catabolic, mechanisms. Considering the impact of AECOPD on muscle function, and that of muscle impairment on the recurrence of exacerbations, counteracting muscle deterioration in AECOPD provides an unprecedented therapeutic opportunity.
肌肉功能障碍在 COPD 中很常见,会对身体机能、疾病负担、生活质量甚至死亡率等方面产生不良的临床影响。在 COPD 急性加重(AECOPD)期间,呼吸症状会恶化,肌肉功能障碍也可能会加重。本报告对过去 20 年在 PubMed 上发表的临床和临床前同行评审文献进行了综述,全面阐述了 AECOPD 在 COPD 肌肉功能障碍中的作用、潜在机制和治疗观点。AECOPD 及其反复发作对 COPD 患者肌肉功能障碍的影响不容忽视,这主要归因于与疾病相关的导致肌肉恶化的驱动因素急性加剧和汇聚,尤其是废用、全身炎症和皮质类固醇治疗。寻找新的治疗方法应该集中在 AECOPD 增强的肌肉功能障碍驱动因素上,以及潜在的主要分解代谢机制上。鉴于 AECOPD 对肌肉功能的影响,以及肌肉功能障碍对加重发作的影响,在 AECOPD 中对抗肌肉恶化提供了一个前所未有的治疗机会。